November 11, 2020

Blue Light Cystoscopy System Approved for Marketing in China; “Blue Light Era” for Precision Treatment of Bladder Cancer Begins

Asieris Announces the Completion of their Series D Round of Financing

Cevira® Endorsed with Level 1A Evidence in Expert Consensus, Establishing a New Benchmark for Non-Invasive Treatment of Cervical Precancerous Lesions

Asieris Announces the Completion of their Series D Round of Financing

Asieris’ CEVIRA® Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

Asieris Announces the Completion of their Series D Round of Financing

Asieris Receives Approval in Australia for Phase I Study of APL-2401 in Patients with FGFR2/3-Driven Advanced Solid Tumors

Asieris Announces the Completion of their Series D Round of Financing

Asieris Pharmaceuticals Appoints Dr. Ningshu Liu as Chief Scientific Officer